# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price ta...
Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price targe...
Piper Sandler analyst David Amsellem reiterates Revance Therapeutics (NASDAQ:RVNC) with a Overweight and lowers the price ta...
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 t...
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $18 ...
With cash, cash equivalents, and short-term investments of $277.1 million as of March 31, 2024, and anticipated revenues and ex...